Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | RBP4 | P02753 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL766847 | 0.85 | ALDH1A1 (0.50) | HTTALDH1A1RBP4LMNAMEN1 | |
| SCHEMBL766986 | 0.85 | PKM (0.54) | HTTPOLBALDH1A1LMNAMEN1 | |
| SCHEMBL10274315 | 0.84 | RBP4 (0.51) | HTTPOLBALDH1A1RBP4LMNA | |
| SCHEMBL10274550 | 0.79 | KMT2A (0.49) | HTTALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL20149901 | 0.76 | ALDH1A1 (0.43) | POLBALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL766137 | 0.76 | RBP4 (0.68) | HTTPOLBALDH1A1RBP4LMNA | |
| SCHEMBL767276 | 0.74 | PKM (0.53) | HTTALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL10274318 | 0.73 | ADAMTS5 (0.44) | HTTMEN1KMT2AMAPTTSHR | |
| SCHEMBL10274716 | 0.73 | PKM (0.52) | HTTALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL766210 | 0.72 | RBP4 (0.61) | ALDH1A1RBP4LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071489-A1 | DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES | RBP4, RBP1, FABP4 | HTT 2237/4885POLB 4135/4885ALDH1A1 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.